NR4A1 and breast carcinoma: Another study, the PHERGain phase II trial, treated 227 patients with early-stage HER2-positive breast cancer with 8-cycles of neoadjuvant trastuzumab and pertuzumab (and endocrine therapy if hormone receptor-positive), and the pCR rate was 37.9%.